These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 26021991)

  • 21. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.
    Walkty A; Karlowsky JA; Adam H; Baxter M; Lagacé-Wiens P; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5707-9. PubMed ID: 23939895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M; García-Castillo M; Bofarull AM; Cantón R;
    Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient.
    Aitken SL; Kontoyiannis DP; DePombo AM; Bhatti MM; Tverdek FP; Gettys SC; Nicolau DP; Nunez CA
    Pediatr Infect Dis J; 2016 Sep; 35(9):1040-2. PubMed ID: 27254038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs.
    Borgatta B; Gattarello S; Mazo CA; Imbiscuso AT; Larrosa MN; Lujàn M; Rello J
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2155-2163. PubMed ID: 28624864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant.
    Peghin M; Maiani M; Castaldo N; Givone F; Righi E; Lechiancole A; Sartor A; Pea F; Livi U; Bassetti M
    Infection; 2018 Apr; 46(2):263-265. PubMed ID: 29086895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal piperacillin/tazobactam in the management of multidrug-resistant Pseudomonas aeruginosa endophthalmitis.
    Pathengay A; Mathai A; Shah GY; Ambatipudi S
    J Cataract Refract Surg; 2010 Dec; 36(12):2210-1. PubMed ID: 21111328
    [No Abstract]   [Full Text] [Related]  

  • 27. ESBL E coli and P. aeruginosa Resistance to Ceftolozane-Tazobactam in a Patient with a Liver Abscess. The Search for an Omnipotent Antibiotic Goes On!
    Teleb M; Soto-Ruiz E; Dominguez DC; Antony S
    Infect Disord Drug Targets; 2018; 18(1):81-85. PubMed ID: 27411471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam.
    Sousa Dominguez A; Perez-Rodríguez MT; Nodar A; Martinez-Lamas L; Perez-Landeiro A; Crespo Casal M
    J Antimicrob Chemother; 2017 Apr; 72(4):1262-1263. PubMed ID: 27999042
    [No Abstract]   [Full Text] [Related]  

  • 29. Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
    Oliver WD; Heil EL; Gonzales JP; Mehrotra S; Robinett K; Saleeb P; Nicolau DP
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1899-901. PubMed ID: 26711770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H; Körber-Irrgang B; Kresken M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
    Bassetti M; Castaldo N; Cattelan A; Mussini C; Righi E; Tascini C; Menichetti F; Mastroianni CM; Tumbarello M; Grossi P; Artioli S; Carannante N; Cipriani L; Coletto D; Russo A; Digaetano M; Losito AR; Peghin M; Capone A; Nicolè S; Vena A;
    Int J Antimicrob Agents; 2019 Apr; 53(4):408-415. PubMed ID: 30415002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes.
    Dietl B; Sánchez I; Arcenillas P; Cuchi E; Gómez L; González de Molina FJ; Boix-Palop L; Nicolás J; Calbo E
    Int J Antimicrob Agents; 2018 Mar; 51(3):498-502. PubMed ID: 29158144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Pragsam AK; Kumar DT; Doss CGP; Iyadurai R; Satyendra S; Rodrigues C; Joshi S; Roy I; Chaudhuri BN; Chitnis DS; Tapan D; Veeraraghavan B
    Indian J Med Microbiol; 2018; 36(1):127-130. PubMed ID: 29735843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.
    Pogue JM; Kaye KS; Veve MP; Patel TS; Gerlach AT; Davis SL; Puzniak LA; File TM; Olson S; Dhar S; Bonomo RA; Perez F
    Clin Infect Dis; 2020 Jul; 71(2):304-310. PubMed ID: 31545346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftolozane-tazobactam for the treatment of multidrug-resistant
    Alessa MA; Almangour TA; Alhossan A; Alkholief MA; Alhokail M; Tabb DE
    Am J Health Syst Pharm; 2018 May; 75(9):e184-e188. PubMed ID: 29691260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What place does ceftolozane/tazobactam have in the treatment of complicated urinary-tract infections?
    Murri R; Sacco E
    Expert Opin Pharmacother; 2021 Aug; 22(11):1377-1379. PubMed ID: 33849371
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful treatment of multidrug-resistant
    Kurtzhalts KE; Mergenhagen KA; Manohar A; Berenson CS
    BMJ Case Rep; 2017 Mar; 2017():. PubMed ID: 28363945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of a complex orthopaedic infection due to extensively drug-resistant
    Hassan S; Kahn MD; Saraiya N; Nori P
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29305368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.
    Shortridge D; Castanheira M; Pfaller MA; Flamm RK
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.